1 / 10

Post Cardiac Arrest Syndrome Market

The whole-body ischemia-reperfusion response that occurs during cardiac arrest and subsequent restoration of systemic<br>circulation results in a series of pathophysiological processes that have been termed as PCAS.<br>

DelveInsight
Télécharger la présentation

Post Cardiac Arrest Syndrome Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Post Cardiac Arrest Syndrome (PCAS) The whole-body ischemia-reperfusion response that occurs during cardiac arrest and subsequent restoration of systemic circulation results in a series of pathophysiological processes that have been termed as PCAS. 01 PCAS components comprise post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunction, the systemic ischemia-reperfusion response and persistent precipitating pathology. 02 An In-Hospital Cardiac Arrest means access is available to medical practitioners in advanced resuscitation techniques, whereas an Out-of-Hospital Cardiac Arrest entails a significant response time for emergency services. 03 The post cardiac arrest period is segmented into four phases includes, immediate post-arrest phase, early post-arrest phase, intermediate phase and recovery phase. 04 • DelveInsight © 2019 | All rights reserved • DelveInsight © 2019 | All rights reserved

  2. PCAS Epidemiology • Approx 2/3 of PCAS associated mortality are due to brain injury and contributes • to life time disability. Germany had the highest diagnosed incident cases of Sudden Cardiac Arrest with 148,438 cases among Europe. • Incident cases of IHSCA* and OHSCA* in Japan was found to be 72,117 and 123,000 in 2016. • More • than 350,000 people are affected each year with out of hospital cardiac arrest in the US. There were 1,150,165 diagnosed incident cases of sudden cardiac arrest (SCA) in 2016 in 7 major markets. • * IHSCA (In Hospital Sudden Cardiac Arrest) and OHSCA (Out of • Hospital Sudden Cardiac Arrest) • DelveInsight © 2019 | All rights reserved

  3. PCAS Market Outlook The United States accounts for the largest Post-Cardiac Arrest Syndrome market size in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. PCAS Market analysis carried out for the period of 2016-2027 demonstrates that PCAS Market size was found out to be USD 547.0 Million in 2016 in seven major markets*. At present, there is no therapy approved for PCAS treatment/prevention and the current standard of neuroprotection is targeted temperature management and controlled Oxygenation. The current treatment approach has shown good results in many cases but still unable to reduce the mortality incidences. Although targeted temperature management has been proven to be very effective and used in PCAS patients, the related adverse events hampers the quality of life of the patients. • *7 Major Markets- United States, EU-5 (Germany, Italy, Spain, France, Germany), Japan • DelveInsight © 2019 | All rights reserved • DelveInsight © 2019 | All rights reserved

  4. PCAS Emerging Drug and Companies Drug- Xenon Company- NeuroproteXeon/ Mallinckrodt The Food and Drug Administration has granted Fast Track designation to xenon gas for inhalation for use in post-cardiac arrest patients. Xenon gas therapy is by NeuroproteXeon/Mallinckrodt. The company is exploring the benefits of Xenon gas as an add-on therapy with current standard therapy Oxygenation and Targeted temperature management. • DelveInsight © 2019 | All rights reserved

  5. Complete Information For complete information on Post-Cardiac Arrest Syndrome Market Insights, Epidemiology & Market Forecast-2028 please click the link below CLICK HERE OR Write Us At  info@delveinsight.com • DelveInsight © 2019 | All rights reserved

  6. About Delveinsight Mission 2 1 3 About To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. Vision DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. • DelveInsight © 2019 | All rights reserved

  7. Services by delveinsight PharmDelve Forecasting OpportunityAssessment Consulting ReportStore MarketIntelligence Competitive Analysis Pipeline • DelveInsight © 2019 | All rights reserved

  8. Contact us info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight • DelveInsight © 2019 | All rights reserved

More Related